Metastatic Carcinoma Clinical Trial
Official title:
A Feasibility Study of Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction for Inoperable Primary or Metastatic Carcinoma (SMART ONE)
This is a multi-site single arm feasibility study of single-fraction Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and/or kidney. Stereotactic ablative body radiation therapy (SABR) is a highly-focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02605811 -
Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT02960282 -
Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
|
||
Completed |
NCT01320241 -
Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture
|
Phase 2 | |
Completed |
NCT02192346 -
α-TEA in Advanced Cancer
|
Phase 1 | |
Completed |
NCT01469598 -
Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04376502 -
Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.
|
N/A | |
Active, not recruiting |
NCT02730923 -
Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)
|
Phase 1/Phase 2 |